Anthropic Buys Coefficient Bio for $400M in Stock
Get the Tech newsletter
Daily tech — startups, AI labs, chips, the launches that shape the next decade. Free.
- Anthropic purchased Coefficient Bio in a $400 million all-stock deal, with sources close to the deal confirming the close to TechCrunch but declining to comment on the figure first reported by The Information and Eric Newcomer.
- Coefficient Bio was using AI to speed up drug discovery and biological research, and its team of roughly 10 people will join Anthropic's health and life sciences group.
- Founders Samuel Stanton and Nathan C. Frey launched Coefficient Bio only eight months ago, both coming from computational drug discovery work at Genentech's Prescient Design.
- The acquisition extends Anthropic's October launch of Claude for Life Sciences, a tool aimed at helping scientific researchers make discoveries, signaling a deliberate vertical push rather than a one-off product release.
- The all-stock structure means the $400 million valuation is tied to Anthropic's equity rather than cash, a common pattern for acquihires of early-stage startups where the talent and technology—not revenue—are the real prize.
Why it matters: Anthropic just paid $400M in stock for a team of ~10 that has been operating for eight months, underscoring how aggressively frontier AI labs are paying up for domain expertise in verticals like drug discovery. Coefficient Bio's founders bring direct computational drug discovery experience from Genentech's Prescient Design, giving Anthropic a credible scientific bench to backstop Claude for Life Sciences against rivals like Insilico and Recursion.
Ask SkimNews
